Lifileucel: the first cellular therapy approved for solid tumours
Trends in Cancer · 2024
DOI: 10.1016/j.trecan.2024.04.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024. Verfasst von Max Julve und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Maximilian.julve@nhs.net. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Maximilian.julve@nhs.net.
- Department of Surgery and Cancer, Imperial College London, Du Cane Road, W12 0HS, London, UK.
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Zitieren
APA
Julve, M., Lythgoe, M. P., Larkin, J., & Furness, A. J. S. (2024). Lifileucel: the first cellular therapy approved for solid tumours. Trends in Cancer. https://doi.org/10.1016/j.trecan.2024.04.003
Vancouver
Julve M, Lythgoe MP, Larkin J, Furness AJS. Lifileucel: the first cellular therapy approved for solid tumours. Trends in Cancer. 2024. doi:10.1016/j.trecan.2024.04.003
BibTeX
@article{Julve2024,
author = {Julve, Max and Lythgoe, Mark P and Larkin, James and Furness, Andrew J S},
title = {Lifileucel: the first cellular therapy approved for solid tumours},
journal = {Trends in Cancer},
year = {2024},
doi = {10.1016/j.trecan.2024.04.003}
}
EUVIMED